592 related articles for article (PubMed ID: 34322129)
1. SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants.
Martínez-Flores D; Zepeda-Cervantes J; Cruz-Reséndiz A; Aguirre-Sampieri S; Sampieri A; Vaca L
Front Immunol; 2021; 12():701501. PubMed ID: 34322129
[TBL] [Abstract][Full Text] [Related]
2. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Elife; 2020 Oct; 9():. PubMed ID: 33112236
[TBL] [Abstract][Full Text] [Related]
3. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
[TBL] [Abstract][Full Text] [Related]
4. Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants.
Lin WS; Chen IC; Chen HC; Lee YC; Wu SC
Front Immunol; 2021; 12():795741. PubMed ID: 34925381
[TBL] [Abstract][Full Text] [Related]
5. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
6. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
[TBL] [Abstract][Full Text] [Related]
7. Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants.
Mittal A; Khattri A; Verma V
PLoS Pathog; 2022 Feb; 18(2):e1010260. PubMed ID: 35176090
[TBL] [Abstract][Full Text] [Related]
8. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
[TBL] [Abstract][Full Text] [Related]
9. Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects.
Arashkia A; Jalilvand S; Mohajel N; Afchangi A; Azadmanesh K; Salehi-Vaziri M; Fazlalipour M; Pouriayevali MH; Jalali T; Mousavi Nasab SD; Roohvand F; Shoja Z;
Rev Med Virol; 2021 May; 31(3):e2183. PubMed ID: 33594794
[TBL] [Abstract][Full Text] [Related]
10. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines.
Singh DD; Parveen A; Yadav DK
Front Cell Infect Microbiol; 2021; 11():777212. PubMed ID: 34970509
[TBL] [Abstract][Full Text] [Related]
12. Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.
Ibarrondo FJ; Hofmann C; Ali A; Ayoub P; Kohn DB; Yang OO
mBio; 2021 Dec; 12(6):e0265621. PubMed ID: 34872349
[TBL] [Abstract][Full Text] [Related]
13. Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection.
Konrath KM; Liaw K; Wu Y; Zhu X; Walker SN; Xu Z; Schultheis K; Chokkalingam N; Chawla H; Du J; Tursi NJ; Moore A; Adolf-Bryfogle J; Purwar M; Reuschel EL; Frase D; Sullivan M; Fry B; Maricic I; Andrade VM; Iffland C; Crispin M; Broderick KE; Humeau LMPF; Patel A; Smith TRF; Pallesen J; Weiner DB; Kulp DW
Cell Rep; 2022 Feb; 38(5):110318. PubMed ID: 35090597
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
15. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
16. Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats.
Tcheou J; Raskin A; Singh G; Kawabata H; Bielak D; Sun W; González-Domínguez I; Sather DN; García-Sastre A; Palese P; Krammer F; Carreño JM
Front Immunol; 2021; 12():791764. PubMed ID: 34868082
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern.
Kovacech B; Fialova L; Filipcik P; Skrabana R; Zilkova M; Paulenka-Ivanovova N; Kovac A; Palova D; Rolkova GP; Tomkova K; Csokova NT; Markova K; Skrabanova M; Sinska K; Basheer N; Majerova P; Hanes J; Parrak V; Prcina M; Cehlar O; Cente M; Piestansky J; Fresser M; Novak M; Slavikova M; Borsova K; Cabanova V; Brejova B; Vinař T; Nosek J; Klempa B; Eyer L; Hönig V; Palus M; Ruzek D; Vyhlidalova T; Strakova P; Mrazkova B; Zudova D; Koubkova G; Novosadova V; Prochazka J; Sedlacek R; Zilka N; Kontsekova E
EBioMedicine; 2022 Feb; 76():103818. PubMed ID: 35078012
[TBL] [Abstract][Full Text] [Related]
18. α-Hemolysin-Aided Oligomerization of the Spike Protein RBD Resulted in Improved Immunogenicity and Neutralization Against SARS-CoV-2 Variants.
Zou J; Jing H; Zhang X; Liu Y; Zhao Z; Duan L; Yuan Y; Chen Z; Gou Q; Xiong Q; Li S; Yang F; Zeng H; Zou Q; Zhang J
Front Immunol; 2021; 12():757691. PubMed ID: 34630436
[TBL] [Abstract][Full Text] [Related]
19. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS
Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668
[TBL] [Abstract][Full Text] [Related]
20. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
Front Immunol; 2021; 12():691715. PubMed ID: 34149735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
